BACKGROUND AND PURPOSE: The necessity for platelet-inhibition testing before
aneurysm treatment in patients premedicated with antiplatelet agents is controversial. Using …

Background and Purpose—Thromboembolic complications constitute a significant source of
morbidity after neurointerventional procedures. Flow diversion using the pipeline …

Purpose The pipeline embolization device (PED) necessitates dual antiplatelet therapy
(APT) to decrease thrombotic complications while possibly increasing bleeding risks. The …

BACKGROUND There is ongoing controversy regarding the optimal antiplatelet regimen,
and extent or even need for platelet function testing surrounding Pipeline flow diverter …

Background Platelet function testing is controversial and not well studied in patients with
neurovascular disease. Objective To evaluate the performance of thromboelastography …

BACKGROUND: Platelet function testing has been proposed to better adjust individualized
antiplatelet treatment for patients undergoing endovascular treatment for intracranial …

Background Pipeline embolization devices (PEDs) are increasingly used in the treatment of
cerebral aneurysms. Yet, major ischemic or hemorrhagic complications after PED treatment …

Background Acute in situ thrombosis is an ischaemic phenomenon during Pipeline
embolisation device (PED) procedures with potentially high morbidity and mortality. There is …

Utilization of flow diverting devices is accompanied with dual antiplatelet therapy to reduce
the risk of thromboembolic events, even though this increases the risk of hemorrhagic …

Background Patients with cerebral aneurysms treated with the Pipeline embolization device
(PED) are maintained on dual antiplatelet therapy (DAPT) to prevent thromboembolic …